Hansen Medical to Exhibit Magellan(TM) Robotic System at Transcatheter Cardiovascular Therapeutics (TCT) Conference
19 10월 2012 - 7:20AM
Marketwired
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in
intravascular robotics, today announced it will exhibit its
Magellan™ Robotic System at the Transcatheter Cardiovascular
Therapeutics (TCT) conference, from October 22-26 at the Miami
Beach Convention Center in Miami, FL. The Company will be
conducting product demonstrations and exhibiting the Magellan
Robotic System at Booth 895.
Additionally, Dr. Barry Katzen, founder and Medical Director of
Baptist Cardiac & Vascular Institute (Baptist Hospital of
Miami) is scheduled to feature the Magellan System in a live aortic
endograft case at the conference on Wednesday, October 24 at 1:00
PM ET.
"We are pleased that our Magellan Robotic System will be further
highlighted at TCT, which is the world's largest educational
meeting focused on interventional vascular procedures," said Bruce
Barclay, president and CEO of Hansen Medical. "Moreover, the live
case scheduled to be performed by Dr. Katzen will provide an
additional opportunity for those in the cardiovascular community to
observe how the Magellan System can enhance endovascular
procedures. Our strong presence at TCT combined with our recent and
upcoming showings at the Vascular InterVentional Advances (VIVA)
Conference and the 39th Annual Symposium on Vascular and
Endovascular Issues (VEITHsymposium™), respectively, are critical
opportunities for Hansen Medical to continue generating momentum
around the significant benefits of our technology."
About the Magellan™ Robotic System Hansen
Medical's Magellan Robotic System is based upon the flexible
robotic technology incorporated in the Sensei-X® Robotic Catheter
System currently sold in the U.S. and Europe, which has been used
in more than 8,000 patients, but includes a number of key
enhancements. In particular, the Magellan Robotic System:
- Provides solid catheter stability for placement of therapeutic
devices.
- Is designed to enable predictable procedure times and increased
case throughput.
- Allows for independent, individual robotic control of the
distal tips of both the outer sheath and the inner leader catheter,
as well as robotic manipulation of standard guidewires.
- Is designed to allow for sufficient extension inside the body
to access hard to reach peripheral anatomy.
- Preserves the open architecture featured in the Sensei System
to allow for the subsequent use of many 6F therapeutic devices on
the market today.
- Is designed to potentially reduce physician radiation exposure
and fatigue by employing a remote physician workstation.
About Hansen Medical, Inc. Hansen Medical,
Inc., based in Mountain View, California, is the global leader in
intravascular robotics, developing products and technology designed
to enable the accurate positioning, manipulation and control of
catheters and catheter-based technologies. The Company's Magellan™
Robotic System, NorthStar™ Robotic Catheter and related
accessories, which are intended to facilitate navigation to
anatomical targets in the peripheral vasculature and subsequently
provide a conduit for manual placement of therapeutic devices, have
undergone both CE marking and 510(k) clearance and are commercially
available in the European Union and the U.S. In the European Union,
the Company's Sensei® X Robotic Catheter System and Artisan Control
Catheter are cleared for use during electrophysiology (EP)
procedures, such as guiding catheters in the treatment of atrial
fibrillation (AF), and the Lynx® Robotic Ablation Catheter is
cleared for the treatment of AF. This robotic catheter system is
compatible with fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data. In the U.S. the Company's Sensei X Robotic
Catheter System and Artisan Control Catheter were cleared by the
U.S. Food and Drug Administration for manipulation and control of
certain mapping catheters in EP procedures. In the United States,
the Sensei System is not approved for use in guiding ablation
procedures; this use remains experimental. The U.S. product
labeling therefore provides that the safety and effectiveness of
the Sensei X System and Artisan Control Catheter for use with
cardiac ablation catheters in the treatment of cardiac arrhythmias,
including AF, have not been established. Additional information can
be found at www.hansenmedical.com.
Forward-Looking Statements This press
release contains forward-looking statements regarding, among other
things, statements relating to goals, plans, objectives, milestones
and future events. All statements, other than statements of
historical fact, are statements that could be deemed
forward-looking statements, including statements containing the
words "plan," "expects," "potential," "believes," "goal,"
"estimate," "anticipates," and similar words. These statements are
based on the current estimates and assumptions of our management as
of the date of this press release and are subject to risks,
uncertainties, changes in circumstances and other factors that may
cause actual results to differ materially from the information
expressed or implied by forward-looking statements made in this
press release. Examples of such statements include statements about
the potential benefits of the Magellan™ Robotic System for
patients, physicians and hospitals and our ability to successfully
market our new products and technologies. Important factors that
could cause actual results to differ materially from those
indicated by such forward-looking statements include, among others:
the rate of adoption of our systems and the rate of use of our
catheters; the uncertain timelines for the sales cycle for newly
introduced products; the commercial viability of our products in
vascular markets; potential safety and regulatory issues that could
slow or suspend our sales; the effect of credit, financial and
economic conditions on capital spending by our potential customers;
the scope and validity of intellectual property rights applicable
to our products; competition from other companies; our ability to
recruit and retain key personnel; our ability to maintain our
remedial actions over previously reported material weaknesses in
internal controls over financial reporting; our ability to manage
expenses and cash flow, and obtain additional financing; and other
risks more fully described in the "Risk Factors" section of our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2012
filed with the SEC on August 9, 2012 and the risks discussed in our
other reports filed with the SEC. Given these uncertainties, you
should not place undue reliance on the forward-looking statements
in this press release. We undertake no obligation to revise or
update information herein to reflect events or circumstances in the
future, even if new information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan
and NorthStar are trademarks of Hansen Medical, Inc. in the United
States and other countries.
Investor Contacts: Peter J. Mariani Chief Financial
Officer Hansen Medical, Inc. 650.404.5800 FTI Consulting,
Inc. Brian Ritchie 212.850.5683 Email Contact 650.404.5800 John
Capodanno 212.850.5705 Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024